
Phase 3 trial shows 70% complete response in low-grade UTUC with Padeliporfin VTP treatment
ImPact Biotech announced updated Phase 3 ENLIGHTED trial results showing 70% complete response in patients with low-grade upper tract urothelial carcinoma (UTUC) treated with Padeliporfin VTP. The treatment demonstrated durable effects, with 85.7% of...


